<DOC>
	<DOCNO>NCT01793688</DOCNO>
	<brief_summary>The purpose survey study following practical use , regard safety effectiveness high-dose administration ( exceed 6 g per day ) UNASYN-S UNASYN-S KIT intravenous use ( UNASYN ) . 1 . Adverse Drug Reaction ( ) expect precaution ( Unexpected Adverse Drug Reaction ) 2 . Incidence status adverse drug reaction 3 . Factors may affect safety effectiveness</brief_summary>
	<brief_title>Drug Use Investigation Of Sulbactam/Ampicillin ( UNASYN ) 12g ( Regulatory Post Marketing Commitment Plan )</brief_title>
	<detailed_description>Implemented Special Investigation central registration system</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Peritonitis</mesh_term>
	<mesh_term>Lung Abscess</mesh_term>
	<mesh_term>Sulbactam</mesh_term>
	<mesh_term>Ampicillin</mesh_term>
	<mesh_term>Sultamicillin</mesh_term>
	<criteria>Patients follow disease receive high dos UNASYN ( exceed 6 g per day ) first dose date second dosing date . 1 ) Pneumonia , 2 ) Lung Abscess , 3 ) Peritonitis Patients age 15 year olde Patients follow disease receive high dos UNASYN ( less 6 g per day ) first dose date second dosing date . 1 ) Pneumonia , 2 ) Lung Abscess , 3 ) Peritonitis Patients age less 15 year .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>UNASYN-S</keyword>
	<keyword>High Dose</keyword>
</DOC>